Login to Your Account



Peptimmune, Novartis Sign $500M Deal for MS Drug

By Catherine Hollingsworth


Tuesday, January 20, 2009
Peptimmune Inc., a privately held U.S. biotechnology company, has granted Novartis AG an exclusive option to license its drug candidate for multiple sclerosis, PI-2301. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription